Avadel Pharmaceuticals plc (NASDAQ:AVDL) has recently been highlighted as one of the Hottest Small Cap Stocks to Buy Now. This recognition comes after Ami Fadia from Needham reiterated a Hold rating on Avadel Pharmaceuticals plc (NASDAQ:AVDL) following the release of the company’s Q3 2025 results on November 4.
In the third quarter, Avadel Pharmaceuticals plc reported a 54.86% year-over-year revenue growth, reaching $77.47 million, which exceeded analysts’ expectations by $3.89 million. Despite this impressive revenue growth, the company fell short of EPS estimates by $0.05, reporting an EPS of $0. Management attributed the revenue increase to strong sales of LUMRYZ, their FDA-approved once-at-bedtime extended-release sodium oxybate therapy for excessive daytime sleepiness in adults and children with narcolepsy. Additionally, the company saw a 48% increase to 3,400 patients on LUMRYZ as of September 30, 2025.
Although Avadel Pharmaceuticals plc missed EPS estimates, the company reported a net income of $20,000 for the quarter, a significant improvement compared to the previous year’s net loss of $2.6 million. This positive result was supported by a $9.5 million reversal by Jazz in conjunction with the Settlement Agreement.
Avadel Pharmaceuticals plc is a biopharmaceutical company focused on developing extended-release drug formulations to enhance patient treatment experiences. Their flagship product, LUMRYZ, has shown promising results in treating excessive daytime sleepiness in patients with narcolepsy.
While Avadel Pharmaceuticals plc shows potential as an investment, some AI stocks may offer greater upside potential with less downside risk. For investors seeking undervalued AI stocks that could benefit from current market trends, exploring alternative investment opportunities may be worthwhile.
Disclosure: None. This article was originally published on Insider Monkey’s website.
